Last updated on May 2019

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML


Brief description of study

This study will evaluate the efficacy and safety of midostaurin in combination with daunorubicin/cytarabine induction, high dose cytarabine consolidation and midostaurin single agent continuation therapy in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML).

Clinical Study Identifier: NCT03280030

Find a site near you

Start Over

Novartis Investigative Site

Shinagawa ku, Japan
3.41miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.